Secreted Bacillus anthracis proteases target the host fibrinolytic system

FEMS Immunology and Medical Microbiology

Volumn 62, Issue 2, 2011, Pages 173-181

  Chung, Myung Chul ^a   Jorgensen, Shelley C ^a   Tonry, Jessica H ^a   Kashanchi, Fatah ^a   Bailey, Charles ^a   Popov, Serguei ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

Bacillus anthracis; Fibrinolysis; InhA; Plasminogen activation system; Protease

Indexed keywords

INHA ENZYME; NPRB ENZYME; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; PROUROKINASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; CONTROLLED STUDY; DOWN REGULATION; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; GENE DELETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; CARBOXYPEPTIDASE U; DISEASE MODELS, ANIMAL; FEMALE; FIBRINOLYSIS; HUMANS; MICE; MICE, INBRED DBA; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; RODENT DISEASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79958830054     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00798.x     Document Type: Article

References (31)

1. Bdeir K, Kuo A, Sachais BS, Rux AH, Bdeir Y, Mazar A, Higazi AA & Cines DB (2003) The kringle stabilizes urokinase binding to the urokinase receptor. Blood 102: 3600-3608.
2. Beaufort N, Wojciechowski P, Sommerhoff CP, Szmyd G, Dubin G, Eick S, Kellermann J, Schmitt M, Potempa J & Magdolen V (2008) The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Biochem J 410: 157-165.
3. Bokarewa MI, Jin T & Tarkowski A (2006) Staphylococcus aureus: staphylokinase. Int J Biochem Cell B 38: 504-509.
4. Bouma BN & Meijers JCM (2003) Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 1: 1566-1574.
5. Chung MC, Popova TG, Millis BA et al. (2006) Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem 281: 31408-31418.
6. Chung MC, Jorgensen SC, Popova TG, Bailey CL & Popov SG (2008) Neutrophil elastase and syndecan shedding contribute to antithrombin depletion in murine anthrax. FEMS Immunol Med Mic 54: 309-318.
7. Chung MC, Jorgensen SC, Popova TG, Tonry JH, Bailey CL & Popov SG (2009) Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection. J Med Microbiol 58: 737-744.
8. Coleman JL & Benach JL (1999) Use of the plasminogen activation system by microorganisms. J Lab Clin Med 134: 567-576.
9. Eaton DL, Malloy BE, Tsai SP, Henzel W & Drayna D (1991) Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 266: 21833-21838.
10. Ellis V (2003) Plasminogen activation at the cell surface. Curr Top Dev Biol 54: 263-312.
11. Kastrup CJ, Boedicker JQ, Pomerantsev AP et al. (2008) Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'. Nat Chem Biol 4: 742-750.
12. Kawamura T, Okada N & Okada H (2002) Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol 46: 225-230.
13. Lack CH (1948) Staphylokinase; an activator of plasma protease. Nature 161: 559-560.
14. Lähteenmäki K, Kuusela P & Korhonen TK (2001) Bacterial plasminogen activators and receptors. FEMS Microbiol Rev 25: 531-552.
15. Lähteenmäki K, Kukkonen M, Jaatinen S, Suomalainen M, Soranummi H, Virkola R, Lång H & Korhonen TK (2003) Yersinia pestis Pla has multiple virulence-associated functions. Adv Exp Med Biol 529: 141-145.
16. Lähteenmäki K, Edelman S & Korhonen TK (2005) Bacterial metastasis: the host plasminogen system in bacterial invasion. Trends Microbiol 13: 79-85.
17. Levi M, de Jonge E & van der Poll T (2004) New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 36: 41-49.
18. Marx PF, Dawson PE, Bouma BN & Meijers JC (2002) Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 41: 6688-6696.
19. Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR & Lisman T (2009) Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94: 811-818.
20. Montuori N & Ragno P (2009) Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci 14: 2494-2503.
21. Mukherjee DV, Tonry JH, Kim KS, Ramarao N, Popova TG, Bailey C, Popov S & Chung MC (2011) Bacillus anthracis protease InhA increases blood-brain barrier permeability and contributes to cerebral hemorrhages. PLoS ONE 6: e17921. DOI: DOI: 10.1371/journal.pone.0017921.
22. Mullarky IK, Szaba FM, Berggren KN, Parent MA, Kummer LW, Chen W, Johnson LL & Smiley ST (2005) Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. Infect Immun 73: 3888-3895.
23. Narasaki R, Kuribayashi H, Shimizu K, Imamura D, Sato T & Hasumi K (2005) Bacillolysin MA, a novel bacterial metalloproteinase that produces angiostatin-like fragments from plasminogen and activates protease zymogens in the coagulation and fibrinolysis systems. J Biol Chem 280: 14278-14287.
24. Rawlings ND, Barrett AJ & Bateman A (2010) MEROPS: the peptidase database. Nucleic Acids Res 38: D227-D233.
25. Rijken DC & Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7: 4-13.
26. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D & Hamsten A (2000) Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84: 364-368.
27. Smith HW & Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23-36.
28. Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G & Kurosawa S (2006) Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol 169: 433-444.
29. Vandeputte-Rutten L, Kramer RA, Kroon J, Dekker N, Egmond MR & Gros P (2001) Crystal structure of the outer membrane protease OmpT from Escherichia coli suggests a novel catalytic site. EMBO J 20: 5033-5039.
30. van Thiel DH, George M & Fareed J (2001) Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 85: 667-670.
31. van Tilburg NH, Rosendaal FR & Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95: 2855-2859.